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Abstract Fanconi anemia (FA) is a recessive disorder
associated with progressive pancytopenia, multiple
developmental defects, and marked predisposition to
malignancies. FA is genetically heterogeneous, com-
prising at least 12 complementation groups (A–M).
Activation of one of the FA proteins (FANCD2) by
mono-ubiquitination is an essential step in DNA
damage response. As FANCD2 interacts with BRCA1,
is expressed in proliferating normal breast cells, and
FANCD2 knockout mice develop breast tumors, we
investigated the expression of FANCD2 in sporadic
and hereditary invasive breast cancer patients to eval-
uate its possible role in breast carcinogenesis. Two
tissue microarrays of 129 and 220 sporadic breast
cancers and a tissue microarray containing 25 BRCA1
germline mutation-related invasive breast cancers were
stained for FANCD2. Expression results were com-
pared with several clinicopathological variables and
tested for prognostic value. Eighteen of 96 (19%)
sporadic breast cancers and two of 21 (10%) BRCA1-
related breast cancers were completely FANCD2-
negative, which, however, still showed proliferation. In
the remaining cases, the percentage of FANCD2-
expressing cells correlated strongly with mitotic index
and percentage of cells positive for the proliferation
markers Ki-67 and Cyclin A. In immunoﬂuorescence
double staining, coexpression of FANCD2 and Ki-67
was apparent. In survival analysis, high FANCD2
expression appeared to be prognostically unfavorable
for overall survival (p = 0.03), independent from other
major prognosticators (p = 0.026). In conclusion,
FANCD2 expression is absent in 10–20% of sporadic
and BRCA1-related breast cancers, indicating that
somatic inactivating (epi)genetic events in FANCD2
may be important in both sporadic and hereditary
breast carcinogenesis. FANCD2 is of independent
prognostic value in sporadic breast cancer.
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Introduction
Fanconi anemia (FA) is a recessive disease with both
autosomal and X-linked inheritance. FA is associated
with progressive pancytopenia, developmental defects,
and marked predisposition to malignancies, especially
acute myeloid leukemia and squamous cell carcinoma
of the head and neck [1, 2]. FA cells are characterized
by spontaneous chromosomal instability and hypersen-
sitivity to DNA cross-linking agents such as mitomycin
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prises at least 12 complementation groups (A–M).
Eleven of the FA genes have been identiﬁed so
far: FANCA, FANCB, FANCC, FANCD1/BRCA2,
FANCD2, FANCE, FANCF, FANCG, FANCJ,
FANCL,a n dFANCM [3–18]. Eight FA proteins (A,
B, C, E, F, G, L, and M) form a nuclear protein com-
plex which is required for mono-ubiquitination of the
downstream FA protein, FANCD2. Activation of
FANCD2 by mono-ubiquitination is an essential step
in the DNA damage response induced by MMC or
ionizing irradiation [2, 10]. This DNA damage
response pathway also includes the breast cancer
susceptibility genes BRCA1 and BRCA2, also referred
to as the FA-BRCA pathway. Following ionizing
radiation, FANCD2 and BRCA1 accumulate and col-
ocalize in nuclear foci, which reﬂect sites of DNA
damage and repair [10, 19]. Like FA cells, cells lacking
BRCA1/2 proteins are hypersensitive to DNA cross-
linking agents. D’Andrea et al. showed that FANCD1
and BRCA2 are the same proteins. BRCA2 is a direct
regulator of RAD51, a protein essential for homolo-
gous recombination repair [20]. Although BRCA1 is
mainly involved in hereditary breast cancer [21], it has
also been implicated in sporadic breast cancer [22]. In
an immunohistochemical analysis, we have previously
shown that FANCD2 is expressed in proliferating cells
of different organs, including the premenopausal
breast duct epithelium [23]. This is in line with the role
of FANCD2 in DNA repair which is important to
guarantee the integrity of the genome during cell rep-
lication [10]. As deregulation of proliferation is one of
the crucial processes of carcinogenesis, these observa-
tions imply a potential role for FANCD2 in the path-
ogenesis of breast cancer. Indeed, FANCD2 knockout
mice develop breast tumors [24]. These considerations
prompted us to investigate the expression of FANCD2
in sporadic and hereditary invasive breast cancers by
immunohistochemistry in relation to several other
proliferation-related biomarkers and survival.
Materials and methods
Tissue microarray
Parafﬁn blocks containing formaldehyde-ﬁxed breast
cancer tissues of 129 cases of invasive breast cancer not
selected for family history (further denoted ‘‘spo-
radic’’) were obtained from the archives of the
Department of Pathology of the VU University Med-
ical Center, Amsterdam. For all breast cancer cases,
age, lymph node status, and tumor size were docu-
mented. A second array block was constructed con-
taining 24 cases with a proven BRCA1 germline
mutation identiﬁed through the Family Cancer Clinic
of the VU University Medical Center as previously
described [25]. Patient characteristics are shown in
Table 1. The hematoxylin–eosin stainings were used to
identify representative areas of tumor tissue in the
blocks. A tissue microarray was then constructed by
transferring tissue cylinders of 4–5 mm from the
representative tumor area of each donor block to the
recipient block using a tissue arrayer (Beecher Instru-
ments, Sun Prairie, WI, USA) as described before [26].
A third tissue array block of 220 sporadic breast cancer
patients with long-term follow-up was obtained from
the archives of the Gerhard-Domagk Institute of
Pathology, University of Muenster, as previously de-
scribed [27].
Sections of 4 lm were cut and transferred on
SuperFrost+ (Menzel&Glaeser, Germany) slides for
immunohistochemistry. Use of anonymous or coded
left over material for scientiﬁc purposes is part of the
standard treatment contract with patients in our
hospital [28].
Immunohistochemistry
Immunohistochemical analysis had been previously
performed on conventional sections for the following
markers: Ki-67, Cyclin A, p21, p27, p53, estrogen
receptor (ER), progesterone receptor (PR), HER-2/
neu, and EGF-receptor [29].
Table 1 Patient characteristics and histology of 120 sporadic and
hereditary breast cancers
Sporadic BRCA1 mutation Total
No. of patients 96 24 120
Age
Mean 65 42 62
Lymph node status
Negative 58 9 67
Positive 38 11 49
Tumor size
Mean 2.34 2.78 2.40
Histological type
Ductal 85 17 102
Lobular 7 1 8
Medullary 1 2 3
Tubular 1 – 1
Cribriform 1 – 1
Apocrine 1 – 1
Metaplastic – 4 4
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generated as previously described [23]. Tissue sections
were deparafﬁnized and rehydrated. Endogenous
peroxidase was blocked with methanol/0.3% H2O2
(20 min). Sections were heated (30 min, 120C) in
0.1 M citrate buffer pH 6. Unspeciﬁc binding was
blocked with a 1:50 normal goat serum in PBS pH 7.4/
1% BSA. Polyclonal rabbit anti-FANCD2 (200 lg/ml)
was diluted 1:500 in PBS/1% BSA, and sections were
incubated overnight (4C) in a humidiﬁed chamber.
Subsequently, sections were incubated with HRP-
conjugated secondary antibodies (EnVision, DAKO)
and diaminobenzidin (10 min), counterstained with
hematoxylin (20 s), dehydrated, and cover-slipped.
Appropriate positive controls were used throughout,
and negative controls were obtained by omission of the
primary antibodies.
Percentages of positively stained nuclei were esti-
mated by an experienced observer (P.J.v.D.), except
for HER-2/neu and EGF-receptor where membrane
staining was scored as positive. In addition, FANCD2
intensity was scored semiquantitatively as 0–3, and an
FANCD2 score was calculated for each case by mul-
tiplying the % FANCD2-positive cells by the staining
intensity.
For FANCD2/Ki-67 double staining, anti-FANCD2
was diluted 1:150, incubated overnight, followed by
incubation with swine anti-Rabbit HRP 1:200 (Dako,
Glostrup, Denmark), and detected with the TSA
TM
Tetramethylrhodamine system (PerkinElmer Life Sci-
ences, Boston, USA). This was immediately followed
by incubation with mouse anti-Ki-67 1:50 (MIB1,
Immunotech, Marseille, France) followed by rabbit
anti-mouse FITC 1:40 (Dako, Glostrup, Denmark).
Nuclei were counterstained by incubation with TO-PRO-3
(Molecular Probes, Eugene, OR, USA) 1:5,000 as
previously described [30].
Statistics
Bivariate scatter plots were generated between the
percentage of FANCD2-expressing cells and the other
continuous features. For the proliferation-associated
features Ki-67, Cyclin A, and MAI, the cases with no
FANCD2 expression were excluded from the analysis,
assuming that FANCD2 is, by some mechanisms, no
longer expressed in these cases. By linear regression
analysis, the correlation coefﬁcient R and related p
values were calculated. Student’s t test was used to
compare FANCD2 expression levels between the low-
level vs. high-level groups for HER-2/neu, the EGF-
receptor, ER (cut off 10%) and PR (cut off 10%), p53
(cut off 10%), and Cyclin D1 (cut off 5%). Prognostic
value of FANCD2 (Muenster cases) was assessed by
computing Kaplan–Meier curves, and differences
between the curves were evaluated with the log-rank
test. Multivariate survival analysis was performed by
Cox regression.
Results
Successful FANCD2 staining was performed in 96 of
the 129 cases of the VUmc sporadic array block. The
drop outs were caused by damaged or detached cores
during cutting, mounting, or staining, or did not con-
tain tumor. Eighteen of these cases (19%) were com-
pletely FANCD2-negative. The other cases showed
variable staining from 1 to 85% of the nuclei. In 21 of
the 24 BRCA1 cases, FANCD2 staining was per-
formed successfully. In two of these (9.5%), FANCD2
expression was completely negative. Figure 1 shows
some representative examples of FANCD2 staining.
The mean percentage of FANCD2-expressing cells
was signiﬁcantly higher in ER-negative patients
(p = 0.019), PR-negative patients (p = 0.016), EGFR-
positive patients (p = 0.002), Cyclin-D1-negative
patients (p = 0.002), and p53-positive patients
(p < 0.001) (Table 2). No statistically signiﬁcant dif-
ference was seen for HER-2/neu. When analyzing the
sporadic and hereditary subgroups, similar associations
were seen. FANCD2 staining intensity yielded no
useful correlations and no prognostic value, and the
FANCD2 score yielded essentially the same correla-
tions and prognostic value as the % FANCD2-positive
cells (data not shown).
In linear regression analysis (Table 3), the percent-
age of FANCD2-expressing cells was signiﬁcantly
positively correlated to Ki-67 (R = 0.502, p < 0.0001),
Cyclin A (R =0 . 4 8 2 , p < 0.0001), MAI (R = 0.506,
p < 0.001), and p53 (R = 0.379, p < 0.0001), and signiﬁ-
cantly negatively correlated to age (R = 0.197, p = 0.033),
ER (R =0 . 2 2 1 ,p = 0.017), and PR (R = 0.204, p = 0.028).
There was no correlation between FANCD2 and the
other continuous features. Figure 2 shows examples of
FANCD2/Ki-67 immunoﬂuorescence double staining,
underlining the coexpression of FANCD2 and Ki-67 in
invasive breast cancers cells. In the Muenster cases,
most of these correlations could be reproduced
(age: p = 0.063, Ki-67: p = 0.001, p53: p = 0.003, ER:
p = 0.034). Only PR was not signiﬁcant here, and
Cyclin A was not performed.
In the regression analysis between the percentages
of FANCD2-expressing cells and Ki-67 and Cyclin A,
the completely negative FANCD2 cases were excluded.
These FANCD2-negative cases had Ki-67 values
Breast Cancer Res Treat (2008) 107:41–47 43
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0 and 50 (mean 10%), and MAI values between 0 and 37
(mean 11), indicating that these cases had (sometimes
even high) FANCD2-independent proliferation.
In survival analysis (sporadic Muenster cases), high
FANCD2 expression appeared to be prognostically
unfavorable (p = 0.03). Figure 3 shows the survival
curves. In Cox regression including tumor size, lymph
node status, ER, and grade, FANCD2 staining ap-
peared to have independent prognostic value for
overall survival (p = 0.026).
Discussion
The aim of this study was to investigate the expression
of FANCD2 in sporadic and hereditary breast cancers.
This was inspired by several observations. First,
FANCD2 and BRCA1/2 are functionally closely linked
Fig. 1 Examples of FANCD2
staining in sporadic (A/B,
A = negative control) and
BRCA1-related breast
cancers (C/D, C = negative
control)
Table 2 Mean percentage of FANCD2-positive cells in high-
and low-level expression groups of hormone receptors, growth
factor receptors, Cyclin D1, and p53 in sporadic and hereditary
breast cancers
Number (%) Mean (SE) of
FANCD2%
p Value
(t test)
Total 117 (100)
ER
Low 56 (48) 14 (2.5) 0.019
High 61 (52) 8 (1.6)
PR
Low 81 (69) 17 (1.9) 0.016
High 36 (31) 12 (1.9)
HER-2/neu
Negative 93 (79) 16 (1.6) 0.797
Positive 24 (21) 17 (3.5)
EGF receptor
Negative 78 (66) 13 (1.5) 0.002
Positive 39 (33) 19 (3.1)
Cyclin D1
Low 85 (73) 12 (1.9) 0.002
High 32 (27) 7 (2.6)
p53
Low 88 (75) 8 (1.3) <0.001
High 29 (25) 19 (4.3)
ER estrogen receptor, PR progesterone receptor
Table 3 Correlation between mean percentage of FANCD2-
expressing cells and other continuous clinicopathological
variables in sporadic and hereditary breast cancers
Feature Rp Value
MAI
a 0.506 <0.001
Ki-67
a 0.502 <0.001
Cyclin A
a 0.482 <0.001
Age –0.197 0.033
ER –0.221 0.017
PR –0.204 0.028
Tumor size 0.018 0.852
p27 –0.074 0.430
p21 –0.171 0.065
p53 0.379 <0.001
Cyclin D1 –0.126 0.176
ER estrogen receptor, PR progesterone receptor
a FANCD2-negative cases excluded
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are implicated in hereditary and sporadic breast
cancers [21, 22]. Second, targeted deletion of FANCD2
in mice resulted in an increased rate of breast tumors
[24]. Third, we have shown that FANCD2 is expressed
in proliferating cells in the duct epithelium of the
normal breast [23].
It appeared that 19% of sporadic breast cancers
completely lacked FANCD2 expression. Yet, these
FANCD2-negative cases had high mean Ki-67, Cyclin
A, and MAI values, indicating that the low FANCD2
levels in these cases cannot be explained by low pro-
liferation. The fact that these FANCD2-negative cases
stained for other proteins makes it quite unlikely that
the FANCD2 negativity is due to ﬁxation problems. In
the FANCD2-negative cases, FANCD2 inactivation
may, in view of its important function, have been a hit
in carcinogenesis. BRCA1 germline mutation-related
breast cancers showed lack of FANCD2 expression in
only 9.5% of cases, which ﬁts with the concept that a
major hit in an important pathway (in these cases the
BRCA1 germline mutation) is usually not associated
with further hits in this pathway. It is yet unclear what
the mechanism behind the lack of FANCD2 expression
in these cases is. It needs to be further studied whether
there are inactivating somatic mutations in these cases
or whether promoter methylation plays a role.
FANCD2 expression was strongly correlated with
expression of the proliferation-associated features
Ki-67, Cyclin A, and MAI, and FANCD2 and Ki-67
were coexpressed in invasive cancer cells. This is
likely a reﬂection of the physiological function of
FANCD2 in DNA repair of proliferating cells, rather
than an independent overexpression of an altered
gene, in line with our previous study where we found
a coexpression of FANCD2 and Ki-67 in proliferat-
ing cells of various normal human tissues [23]. The
observation that high FANCD2 expression indicated
poor prognosis ﬁts within the same concept, as rate
of proliferation (and thereby FANCD2 expression) is
a major cell biological phenomenon determining
prognosis [31–33]. FANCD2 had prognostic value
independent of stage and grade, which can be
explained by the fact that proliferation and stage are
not strongly correlated, and that grade includes nu-
clear atypia and tubule formation besides rate of
proliferation as measured by mitotic index.
Although heterozygosity for p53 was shown to
accelerate epithelial tumor formation in Fancd2
knockout mice [34], a functional link between p53 and
Fancd2 has not been described to explain the associa-
tion found in the present study, which is likely caused
by the fact that p53 mutated and thereby p53 protein
accumulated tumors show, in general, higher proliferation
and therefore more proliferating FANCD2-expressing
cells. The same may also hold for the relation between
FANCD2 and EGFR expressions, for which also no
functional relationship has been described.
The negative relation between FANCD2 and age
can likely be explained by the fact that BRCA1-related
Fig. 2 FANCD2/Ki-67 immunoﬂuorescence double staining in a
representative case of invasive breast cancer. Top left: Ki-67
staining. Top right: FANCD2 staining. Bottom left: TO-PRO
staining. D: Triple exposure showing coexpression of FANCD2
and Ki-67
Fig. 3 Prognostic value of FANCD2 expression in sporadic
invasive breast cancer. Low expressors have a better survival
than high expressors (p = 0.03, N = 122)
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123patients that have higher FANCD2 expression are
younger.
Within the light of the above observations, the
questionremains why FANCD2patientsdonot seem to
be predisposed to breast cancer in clinical practice. FA
itself is a rare genetic disease where the complementa-
tion group D2 constitutes only 1–2% of all FA cases and
these patients generally have a more severe clinical
course. They may therefore simply not live to get breast
cancer in an apparent increased frequency. Our results
do not indicate that somatic (epi)genetic changes in
FANCD2 are a frequent secondary carcinogenetic
event in BRCA1 germline-mutated patients, although
this needs to be conﬁrmed in a larger study group.
In conclusion, FANCD2 expression is absent in 10–
20% of sporadic and BRCA1-related breast cancers,
indicating that somatic inactivating (epi)genetic events
in FANCD2 may be important in both sporadic and
hereditary breast carcinogenesis. FANCD2 is of inde-
pendent prognostic value in sporadic breast cancer.
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